Ophthalmology Innovation Summit - Retina

Name: RFE Pharma
Uploaded: 2018-07-23T15:22:00+00:00
Description: Alan Franklin, MD, PhD, Chief Medical Officer, RFE Pharma, provides an update on lead compound RFE-007-CAI (carboxyamidotriazole), which the company has reformulated as an anti-angiogenic intravitreal injectable formulation.

OIS Retina: 2018

RFE Pharma

Alan Franklin, MD, PhD

Show Description +

Alan Franklin, MD, PhD, Chief Medical Officer, RFE Pharma, provides an update on lead compound RFE-007-CAI (carboxyamidotriazole), which the company has reformulated as an anti-angiogenic intravitreal injectable formulation.

Posted: 7/23/2018

Up Next

EyePoint Pharmaceuticals

Tom Hadley

Zeiss

ZeaVision Holdings

Pinakin Davey, OD, PhD

iRenix

Stephen Smith, MD

Clearside Biomedical

Brion Raymond

Aerie Pharmaceuticals

Vince Anido Jr, PhD

Spark Therapeutics

Paulo Falabella, MD, PhD

Allegro

Vicken Karageozian, MD

Eyedaptic

Jay Cormier

GenSight Biologics

Barrett Katz, MD

Back to All Videos

RFE Pharma

Alan Franklin, MD, PhD

Alan Franklin, MD, PhD, Chief Medical Officer, RFE Pharma, provides an update on lead compound RFE-007-CAI (carboxyamidotriazole), which the company has reformulated as an anti-angiogenic intravitreal injectable formulation.

Posted: 7/23/2018